Catalyst Pharmaceuticals (CPRX) Other Non-Current Liabilities (2010 - 2026)
Catalyst Pharmaceuticals posted quarterly Other Non-Current Liabilities of $280000.0 for Q1 2026, up 8.11% year-on-year from $259000.0 in Q1 2025, and up 33.97% on a QoQ basis from $209000.0 in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 15 years of Other Non-Current Liabilities data on file, last reported at $280000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 8.11% year-over-year to $280000.0; the trailing twelve-month figure through Mar 2026 stood at $280000.0 (up 8.11% YoY), and the FY2025 full-year result was $209000.0, down 33.65% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $280000.0, up from $209000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $14.7 million in Q3 2022 and bottomed at $161000.0 in Q3 2025.
- The 5-year median for Other Non-Current Liabilities is $2.6 million (2024), against an average of $4.7 million.
- The widest annual swing landed in 2025, when Other Non-Current Liabilities slumped 94.22%; it then advanced 8.11% in 2026.
- A 5-year view of Other Non-Current Liabilities shows it stood at $14.1 million in 2022, then sank by 78.8% to $3.0 million in 2023, then plunged by 89.44% to $315000.0 in 2024, then sank by 33.65% to $209000.0 in 2025, then surged by 33.97% to $280000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $280000.0 (Q1 2026), $209000.0 (Q4 2025), and $161000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 280,000.00 |
| Dec 31, 2025 | 209,000.00 |
| Sep 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 309,000.00 |
| Mar 31, 2025 | 259,000.00 |
| Dec 31, 2024 | 315,000.00 |
| Sep 30, 2024 | 2.79 Mn |
| Jun 30, 2024 | 2.40 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Dec 31, 2023 | 2.98 Mn |
| Sep 30, 2023 | 3.58 Mn |
| Jun 30, 2023 | 12.72 Mn |
| Mar 31, 2023 | 13.39 Mn |
| Dec 31, 2022 | 14.06 Mn |
| Sep 30, 2022 | 14.75 Mn |
| Jun 30, 2019 | 801,264.00 |
| Dec 31, 2018 | 154,799.00 |
| Sep 30, 2018 | 164,781.00 |
| Jun 30, 2018 | 143,335.00 |
| Mar 31, 2018 | 150,395.00 |
| Dec 31, 2017 | 157,456.00 |
| Sep 30, 2017 | 164,516.00 |
| Jun 30, 2017 | 170,519.00 |
| Mar 31, 2017 | 519,461.00 |
| Dec 31, 2016 | 122,226.00 |
| Sep 30, 2016 | 185,095.00 |
| Jun 30, 2016 | 188,032.00 |
| Mar 31, 2016 | 275,007.00 |
| Dec 31, 2015 | 176,293.00 |
| Sep 30, 2015 | 1.40 Mn |
| Jun 30, 2015 | 12,452.00 |
| Mar 31, 2015 | 3.56 Mn |
| Dec 31, 2014 | 15,839.00 |
| Sep 30, 2014 | 3.27 Mn |
| Jun 30, 2014 | 2.36 Mn |
| Mar 31, 2014 | 2.14 Mn |
| Dec 31, 2013 | 1.82 Mn |
| Sep 30, 2013 | 20,040.00 |
| Jun 30, 2013 | 20,653.00 |
| Mar 31, 2013 | 21,265.00 |
| Dec 31, 2012 | 498,587.00 |
| Sep 30, 2012 | 1.93 Mn |
| Jun 30, 2012 | 594,114.00 |
| Mar 31, 2012 | 21,845.00 |
| Dec 31, 2011 | 9,518.00 |
| Dec 31, 2010 | 14,748.00 |